Shares of Kane Biotech Inc. (CVE:KNE – Get Free Report) traded up 16.7% during mid-day trading on Wednesday . The stock traded as high as C$0.04 and last traded at C$0.04. 1,263,508 shares changed hands during trading, an increase of 524% from the average session volume of 202,403 shares. The stock had previously closed at C$0.03.
Kane Biotech Stock Performance
The company has a debt-to-equity ratio of -308.66, a current ratio of 0.68 and a quick ratio of 0.39. The firm has a 50 day simple moving average of C$0.03 and a 200-day simple moving average of C$0.04. The company has a market cap of C$6.36 million, a price-to-earnings ratio of -1.75 and a beta of 1.03.
Kane Biotech Company Profile
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
Featured Stories
- Five stocks we like better than Kane Biotech
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
